Shanghai TheraMabs Bio-technology co., LTD

Purchase

Description

TRULICITY contains dulaglutide, a human GLP-1 receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37). Structural modifications were introduced in the GLP-1 part of the molecule responsible for interaction with the enzyme dipeptidyl-peptidase-IV (DPP-4). Additional modifications were made in an area with a potential T-cell epitope and in the areas of the IgG4 Fc part of the molecule responsible for binding the high-affinity Fc receptors and half-antibody formation. The overall molecular weight of dulaglutide is approximately 63 kilodaltons.

Dulaglutide is supplied at a concentration of 3 mg/mL as a clear, colorless, sterile solution, which contains 0.14 mg/mL citric acid anhydrous, 46.4 mg/mL mannitol, 0.20 mg/mL polysorbate 80, 2.74 mg/mL trisodium citrate dihydrate.

Properties

Supply Ability

20 kilogram per year, 1 Gram（Min. Order）.

Material Safety Data Sheet

If you need more information, please contact us.

Certificate Of Analysis

If you need more information, please contact us.

Detail information about the product please refer the website below:

https://en.wikipedia.org/wiki/Dulaglutide